Some parents fear changes to state laws as FDA weighs use of CBD pharmaceuticals

Some parents fear changes to state laws as FDA weighs use of CBD pharmaceuticals

COLORADO SPRINGS — Some American parents who for decades have used cannabis to treat severe forms of epilepsy in their kids are feeling more cautious than celebratory as U.S. regulators near a decision on whether to approve the first drug derived from the marijuana plant.

The U.S. Food and Drug Administration is expected to issue a decision by the end of the month on the medication Epidiolex, made by GW Pharmaceuticals. It’s a purified form of cannabidiol — a part of cannabis that doesn’t get users — to deal with Dravet and Lennox-Gastaut syndromes in kids. Both forms of epilepsy are rare.

Cannabidiol’s effect on a variety of health conditions is often touted, but there is still little evidence to back up advocates’ personal experiences. The U.S. Drug Enforcement Administration has long categorized cannabis as a Schedule I drug, a category with “no currently accepted medical use and a high potential for abuse. ” That strictly limits research on potential medical uses for cannabis or the chemicals inside, such as cannabidiol, or CBD.

Read the rest of this story on DenverPost.com.

Published at Wed, 20 Jun 2018 12:04:54 +0000

Posted in: News

Comments are closed.